ProCE Banner Activity

ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC

Slideset Download
Conference Coverage
Results of the largest controlled trial in metastatic nonclear-cell RCC show different efficacy among the VEGF-TKI and mTOR inhibitor in specific subgroups.

Released: June 04, 2015

Expiration: June 02, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation